Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3.

Clinical Immunology

Volumn 158, Issue 1, 2015, Pages 114-125

  Golden Mason, Lucy ^a   Waasdorp Hurtado, Christine E ^b   Cheng, Linling ^a   Rosen, Hugo R ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytotoxicity; HCV; Human; IFN ; Natural cytotoxicity receptors

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; MEMBRANE RECEPTOR; MUCIN DOMAIN CONTAINING MOLECULE 3; PEGINTERFERON ALPHA2A; RIBAVIRIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE; HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEGRANULATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; UPREGULATION; VIRAL CLEARANCE; AGED; CASE CONTROL STUDY; CHRONIC HEPATITIS C; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION; YOUNG ADULT;

EID: 84927721874     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.008     Document Type: Article

References (46)

1. Weiss R.A., McMichael A.J. Social and environmental risk factors in the emergence of infectious diseases. Nat. Med. 2004, 10:S70-S76.
2. Rosen H.R. Emerging concepts in immunity to hepatitis C virus infection. J. Clin. Invest. 2013, 123:4121-4130.
3. Wang C.C., Krantz E., Klarquist J., Krows M., McBride L., Scott E.P., Shaw-Stiffel T., Weston S.J., Thiede H., Wald A., Rosen H.R. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J. Infect. Dis. 2007, 196:1474-1482.
4. Ha S.J., West E.E., Araki K., Smith K.A., Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol. Rev. 2008, 223:317-333.
5. Virgin H.W., Wherry E.J., Ahmed R. Redefining chronic viral infection. Cell 2009, 138:30-50.
6. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., Wong J.C., Satkunarajah M., Schweneker M., Chapman J.M., Gyenes G., Vali B., Hyrcza M.D., Yue F.Y., Kovacs C., Sassi A., Loutfy M., Halpenny R., Persad D., Spotts G., Hecht F.M., Chun T.W., McCune J.M., Kaul R., Rini J.M., Nixon D.F., Ostrowski M.A. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 2008, 205:2763-2779.
7. Sakhdari A., Mujib S., Vali B., Yue F.Y., MacParland S., Clayton K., Jones R.B., Liu J., Lee E.Y., Benko E., Kovacs C., Gommerman J., Kaul R., Ostrowski M.A. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One 2012, 7:e40146.
8. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., Castelblanco N., Kuchroo V., Gretch D.R., Rosen H.R. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 2009, 83:9122-9130.
9. McMahan R.H., Golden-Mason L., Nishimura M.I., McMahon B.J., Kemper M., Allen T.M., Gretch D.R., Rosen H.R. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 2010, 120:4546-4557.
10. Moorman J.P., Wang J.M., Zhang Y., Ji X.J., Ma C.J., Wu X.Y., Jia Z.S., Wang K.S., Yao Z.Q. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J. Immunol. 2012, 189:755-766.
11. Gorman J.V., Colgan J.D. Regulation of T cell responses by the receptor molecule Tim-3. Immunol. Res. 2014, 59(1-3):56-65.
12. Han G., Chen G., Shen B., Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Front. Immunol. 2013, 4:449.
13. Qiu Y., Chen J., Liao H., Zhang Y., Wang H., Li S., Luo Y., Fang D., Li G., Zhou B., Shen L., Chen C.Y., Huang D., Cai J., Cao K., Jiang L., Zeng G., Chen Z.W. Tim-3-expressing CD4+ and CD8+ T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions. PLoS Pathog. 2012, 8:e1002984.
14. Zhang Y., Ma C.J., Wang J.M., Ji X.J., Wu X.Y., Moorman J.P., Yao Z.Q. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J. Leukoc. Biol. 2012, 91:189-196.
15. Chiba S., Baghdadi M., Akiba H., Yoshiyama H., Kinoshita I., Dosaka-Akita H., Fujioka Y., Ohba Y., Gorman J.V., Colgan J.D., Hirashima M., Uede T., Takaoka A., Yagita H., Jinushi M. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 2012, 13:832-842.
16. Finney C.A., Ayi K., Wasmuth J.D., Sheth P.M., Kaul R., Loutfy M., Kain K.C., Serghides L. HIV infection deregulates Tim-3 expression on innate cells: combination antiretroviral therapy results in partial restoration. J. Acquir. Immune Defic. Syndr. 2013, 63:161-167.
17. Gleason M.K., Lenvik T.R., McCullar V., Felices M., O'Brien M.S., Cooley S.A., Verneris M.R., Cichocki F., Holman C.J., Panoskaltsis-Mortari A., Niki T., Hirashima M., Blazar B.R., Miller J.S. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012, 119:3064-3072.
18. Ndhlovu L.C., Lopez-Verges S., Barbour J.D., Jones R.B., Jha A.R., Long B.R., Schoeffler E.C., Fujita T., Nixon D.F., Lanier L.L. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012, 119:3734-3743.
19. Ju Y., Hou N., Meng J., Wang X., Zhang X., Zhao D., Liu Y., Zhu F., Zhang L., Sun W., Liang X., Gao L., Ma C. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J. Hepatol. 2010, 52:322-329.
20. Biron C.A. Initial and innate responses to viral infections-pattern setting in immunity or disease. Curr. Opin. Microbiol. 1999, 2:374-381.
21. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., Yokoyama W.M., Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
22. Biron C.A., Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 2001, 13:458-464.
23. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol. 2001, 22:633-640.
24. Lanier L.L. Missing self, NK cells, and the White Album. J. Immunol. 2005, 174:6565.
25. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 2005, 23:225-274.
26. Moretta A., Bottino C., Sivori S., Marcenaro E., Castriconi R., Della Chiesa M., Carlomagno S., Augugliaro R., Nanni M., Vitale M., Millo R. Natural killer lymphocytes: "null cells" no more. Ital. J. Anat. Embryol. 2001, 106:335-342.
27. Golden-Mason L., Rosen H.R. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol. Rev. 2013, 255:68-81.
28. Bonavita M.S., Franco A., Paroli M., Santilio I., Benvenuto R., De Petrillo G., Levrero M., Perrone A., Balsano C., Barnaba V. Normalization of depressed natural killer activity after interferon-alpha therapy is associated with a low frequency of relapse in patients with chronic hepatitis C. Int. J. Tissue React. 1993, 15:11-16.
29. Corado J., Toro F., Rivera H., Bianco N.E., Deibis L., De Sanctis J.B. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin. Exp. Immunol. 1997, 109:451-457.
30. Par G., Rukavina D., Podack E.R., Horanyi M., Szekeres-Bartho J., Hegedus G., Paal M., Szereday L., Mozsik G., Par A. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. J. Hepatol. 2002, 37:514-522.
31. Ahmad A., Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J. Leukoc. Biol. 2004, 76:743-759.
32. Meier U.C., Owen R.E., Taylor E., Worth A., Naoumov N., Willberg C., Tang K., Newton P., Pellegrino P., Williams I., Klenerman P., Borrow P. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 2005, 79:12365-12374.
33. Nattermann J., Feldmann G., Ahlenstiel G., Langhans B., Sauerbruch T., Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2006, 55:869-877.
34. De Maria A., Fogli M., Mazza S., Basso M., Picciotto A., Costa P., Congia S., Mingari M.C., Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 2007, 37:445-455.
35. Mondelli M.U., Oliviero B., Mele D., Mantovani S., Gazzabin C., Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?. Front. Immunol. 2012, 3:351.
36. Sharma S., Sundararajan A., Suryawanshi A., Kumar N., Veiga-Parga T., Kuchroo V.K., Thomas P.G., Sangster M.Y., Rouse B.T. T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:19001-19006.
37. Golden-Mason L., Castelblanco N., O'Farrelly C., Rosen H.R. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. J. Virol. 2007, 81:9292-9298.
38. Golden-Mason L., Bambha K.M., Cheng L., Howell C.D., Taylor M.W., Clark P.J., Afdhal N., Rosen H.R., Virahep C.S.G. Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 2011, 54:1559-1569.
39. Stegmann K.A., Bjorkstrom N.K., Veber H., Ciesek S., Riese P., Wiegand J., Hadem J., Suneetha P.V., Jaroszewicz J., Wang C., Schlaphoff V., Fytili P., Cornberg M., Manns M.P., Geffers R., Pietschmann T., Guzman C.A., Ljunggren H.G., Wedemeyer H. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010, 138:1885-1897.
40. Mattei F., Schiavoni G., Belardelli F., Tough D.F. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 2001, 167:1179-1187.
41. Rudd B.D., Luker G.D., Luker K.E., Peebles R.S., Lukacs N.W. Type I interferon regulates respiratory virus infected dendritic cell maturation and cytokine production. Viral Immunol. 2007, 20:531-540.
42. Golden-Mason L., Cox A.L., Randall J.A., Cheng L., Rosen H.R. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology 2010, 52:1581-1589.
43. Golden-Mason L., Stone A.E., Bambha K.M., Cheng L., Rosen H.R. Race- and gender-related variation in natural killer p46 expression associated with differential anti-hepatitis C virus immunity. Hepatology 2012, 56:1214-1222.
44. Ahlenstiel G., Titerence R.H., Koh C., Edlich B., Feld J.J., Rotman Y., Ghany M.G., Hoofnagle J.H., Liang T.J., Heller T., Rehermann B. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010, 138:325-335. (e321-322).
45. Anderson A.C. Editorial: Tim-3 puts on the brakes. J. Leukoc. Biol. 2012, 91:183-185.
46. da Silva I.P., Gallois A., Jimenez-Baranda S., Khan S., Anderson A.C., Kuchroo V.K., Osman I., Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2014, 2:410-422.